Company Cerevel Therapeutics Holdings, Inc.
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.12 USD | -0.53% | -0.20% | -0.70% |
Business Summary
Number of employees: 355
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 42 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Raymond Sanchez
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-12-31 |
John Renger
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-04-30 |
53 | - | ||
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Scott Akamine
LAW | General Counsel | 40 | 21-05-23 |
Mark Bodenrader
AUD | Comptroller/Controller/Auditor | 51 | 19-08-31 |
Paul Burgess
PRN | Corporate Officer/Principal | 50 | 23-06-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 18-08-31 |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Deval Patrick
BRD | Director/Board Member | 67 | 21-01-19 |
Marijn Dekkers
BRD | Director/Board Member | 65 | 18-08-31 |
Norbert Riedel
BRD | Director/Board Member | 66 | 18-11-30 |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director/Board Member | 51 | 18-08-31 | |
Adam Koppel
BRD | Director/Board Member | 54 | 18-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 182,194,722 | 77,490,691 ( 42.53 %) | 0 | 42.53 % |
Company contact information
Cerevel Therapeutics Holdings, Inc.
222 Jacobs Street Suite 200
02141, Cambridge
+844 304 2048
http://www.cerevel.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.12% | 7.72B | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.23% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- CERE Stock
- Company Cerevel Therapeutics Holdings, Inc.